Ann: Results of Meeting, page-21

Interesting choice of adjectives from Argonauts in describing the current stage:

"BOT is pregnant with news flow, and from early next calendar year, there will be a number of key announcements that if positive, will further de-risk the company and set it up for the next iteration of growth. We maintain our Speculative Buy recommendation with a price target of $0.20, and we ascribe no value to BTX 1801 at this time."

Sounds like octuplets to me...

BP 's looking at those kids schooling years already, with yearly revenues for both BTX1503 and BTX1204 in 6 years time (with FDA's approval) starting @$100m:

"BTX1204 is likely to be highly differentiated from its competitors as it is a new agent with a novel mechanism of action. For BTX1204 we estimate the annual revenue per user to be approximately US$4,500."